Han Qi, Shi Junqi, Liu Jiaojiao, Fu Yang, Li Zhongxun, Guo Huina, Guan Xiaoya, Xue Xuting, Liu Hongliang, Zhao Liting, Zhang Chunming
Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, China.
Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, China.
Front Pharmacol. 2024 Apr 5;15:1375110. doi: 10.3389/fphar.2024.1375110. eCollection 2024.
Head and neck cancer is one of the most common tumors worldwide. However, drug resistance in its treatment has become a major factor limiting the efficacy. This study aims to comprehensively understand the current status of research in this field.
The study analyzes papers related to therapeutic resistance in head and neck cancer published between 2000 and 2023 in the Web of Science Core Collection To achieve the research objectives, we searched the WoSCC for research and review papers on therapeutic resistance in head and neck cancer from 2000 to 2023, screened the English literature, and analyzed the research hotspots, academic collaborations, and trends in detail using tools such as Citespace, SCImago Graphica, and VOS viewer.
This study summarizes 787 head and neck cancer treatment resistance publications from WoSCC. The analysis showed that China and the United States are the major contributors in this field, and Grandis Jennifer R and Yang Jai-Sing are the key scholars. Keyword analysis showed that "cisplatin resistance" is a continuing focus of attention, while "Metastasis" and "Ferroptosis" may be emerging research hotspots. Literature clustering analysis pointed out that "Ferroptosis", "Immunotherapy" and "ERK signaling" were the recent hotspots that received extensive attention and citations. Finally, we discuss the current status and challenges in drug-resistant therapies for head and neck cancer.
This study is the first comprehensive bibliometric analysis of drug resistance in head and neck cancer. Reveals current trends and helps researchers grasp cutting-edge hotspots in the field.
头颈癌是全球最常见的肿瘤之一。然而,其治疗中的耐药性已成为限制疗效的主要因素。本研究旨在全面了解该领域的研究现状。
本研究分析了2000年至2023年发表在《科学引文索引核心合集》中与头颈癌治疗耐药性相关的论文。为实现研究目标,我们在科学引文索引核心合集中搜索了2000年至2023年关于头颈癌治疗耐药性的研究和综述论文,筛选了英文文献,并使用Citespace、SCImago Graphica和VOS viewer等工具详细分析了研究热点、学术合作及趋势。
本研究总结了来自科学引文索引核心合集的787篇头颈癌治疗耐药性出版物。分析表明,中国和美国是该领域的主要贡献者,格兰迪斯·珍妮弗·R和杨在升是关键学者。关键词分析显示,“顺铂耐药性”一直是关注焦点,而“转移”和“铁死亡”可能是新兴研究热点。文献聚类分析指出,“铁死亡”“免疫疗法”和“ERK信号传导”是近期受到广泛关注和引用的热点。最后,我们讨论了头颈癌耐药治疗的现状和挑战。
本研究是对头颈癌耐药性的首次全面文献计量分析。揭示了当前趋势,有助于研究人员把握该领域的前沿热点。